WHO International Biological Reference Preparations Held and distributed by the WHO International Laboratories for Biological Standards
|
|
|
- Gillian Marsh
- 5 years ago
- Views:
Transcription
1 WHO International Biological Preparations Anthrax spore vaccine. Lyophilized spore suspension of Bacillus anthracis strain 34 F2. 1 IU / ampoule. Anti-brucella abortus serum, bovine. Lyophilized. 1,000 IU / ampoule of agglutinating; 1,000 IU / ampoule of complement-fixing activity. Anti-dengue virus type 1,2,3 and 4 serum. Freeze-dried 100 units per serotype per ampoule BCG vaccine. Lyophilized. 2.5 mg of semi-dry bacillary mass / 5-ml ampoule. Cholera vaccine (Inaba). Lyophilized. 40,000,000,000 organisms / ampoule. Cholera vaccine (Ogawa). Lyophilized. 40,000,000,000 organisms / ampoule. Clostridium novyi alpha toxoid. Lyophilized. No unitage assigned. Clostridium perfringens beta toxoid. Lyophilized. No unitage assigned. Preparation, 1978 Standard, st- Reagent, Preparation, 1965 Preparation, 1971 Preparation, 1971 Preparation, 1966 Preparation, 1975 No. 638, 30th Report Antigen NIBSC AxV No. 594, 27th Report Bovine serum NIBSC BaDS To be published Human plasma NIBSC 02/ No. 329, 18th Report Antigen NIBSC BCG No. 486, 24th Report Antigen NIBSC INV Rev. 1 No. 486, 24th Report Antigen NIBSC OGV No. 361, 19th Report Toxoid NIBSC CoT No. 594, 27th Report Toxoid NIBSC CWBetatd Page 1 of 6
2 WHO International Biological Preparations Clostridium perfringens epsilon toxoid. Lyophilized. No unitage assigned. Preparation, 1975 No. 594, 27th Report Antigen NIBSC CW Epsilontd Diphtheria (schick) test toxin. Lyophilized. 900 IU / ampoule. Standard, 1954 No. 96, 8th Report Toxin NIBSC STT Diphtheria toxoid, adsorbed. Lyophilized. 160 IU / ampoule. Standard, 1999 No. 904, 50th Report Adsorbed toxoid NIBSC 98/ Diphtheria toxoid, for flocculation tests. Lyophilized. 900 Lf IU / ampoule. Endotoxin for Limulus Amoebocyte Lysate (LAL) gelation tests. Lyophilized. 10,000 IU / ampoule. Haemophilus influenza type b capsular polysaccharide. Lyophilized ± mg/ampoule of polyribosyl ribitol phosphate (PRP) Hepatitis A vaccine, inactivated. Frozen. 100 IU / ml of immunogenic activity; 100 IU / ml of antigen content. Reagent, 1988 Standard, 1996 Standard, 2005 Standard, 1999 No. 786, 39th Report Toxoid NIBSC DIFT No. 878, 47th Report Toxin NIBSC 94/ Rev. 1 To be published Antigen NIBSC 02/ No. 904, 50th Report Antigen NIBSC 95/ MAPREC analysis of poliovirus type 3 (Sabin). Lyophilized. 0.9% 472-C nucleotide / vial. Standard, 1996 No. 878, 47th Report NIBSC 95/ MAPREC analysis of poliovirus type 3 (Sabin), high virus reference. Lyophilized. 1.1% 472-C nucleotide / vial. 1st- Reagent, 1997 No. 889, 48th Report NIBSC 96/ Page 2 of 6
3 WHO International Biological Preparations MAPREC analysis of poliovirus types 3 (Sabin), low virus reference. Lyophilized. 0.7% 472-C nucleotide / vial. 1st- Reagent, 1997 No. 889, 48th Report NIBSC 96/ MAPREC assay for poliovirus type 2. Lyophilized. 0.67% 481- G per ampoule Standard, 2003 NIBSC 97/ MAPREC assay of poliovirus type 2 (481-G control). Lyophilized. 93.5% 481-G per ampoule 1st- Reagent, 2003 NIBSC 98/ MAPREC assay of poliovirus type 2 (high mutant virus). Lyophilized. 1.21% 481-G per ampoule 1st- Reagent, 2003 NIBSC 98/ MAPREC assay of poliovirus type 2 (low mutant virus). Lyophilized. 0.65% 481-G per ampoule 1st- Reagent, 2003 NIBSC 97/ Measles vaccine (live). Lyophilized. 4.3 log10 (20 000) infectious units / vial. measles virus NIBSC 92/ Mumps vaccine (live). Lyophilized. 4.6 log10 (40000) infectious units / vial. mumps virus NIBSC 90/ Newcastle (Hitchner B1 strain) disease vaccine, live. Lyophilized. No unitage assigned. Preparation, 1967 No. 384, 20th Report newcastle virus NIBSC NV Page 3 of 6
4 WHO International Biological Preparations Newcastle disease vaccine (inactivated). Lyophilized. 525 IU / ampoule. Opacity. 10 IU of opacity. Standard, th-International Standard, 1975 No. 274, 16th Report Antigen NIBSC NVIA No. 594, 27th Report Miscellaneous NIBSC 76/ Pertussis serotype 2, typing serum (anti-bordetella pertussis fimbriae). No assigned value 1st- Reagent, 2004 In press Monoclonal IgG (mouse) NIBSC 04/ Pertussis serotype 3, typing serum (anti-bordetella pertussis fimbriae). No assigned value 1st- Reagent, 2004 In press Monoclonal IgG (mouse) NIBSC 04/ Pertussis Toxin, purified. Liquid IU / ampoule. Standard, 2003 In press Toxin NIBSC JNIH Pertussis vaccine. Lyophilized. 46 IU / ampoule. Standard, 1998 No. 897, 49th Report bordetella pertussis NIBSC 66/ Poliomyelitis vaccine (inactivated). Lyophilized. Type 1 antigen: 430 D-antigen units / ml, Type 2 antigen: 95 D-antigen units / ml, Type 3 antigen: 285 D-antigen units / ml. polioviruses NIBSC 91/ Poliomyelitis vaccine, oral log10 TCID 50/ml poliovirus type log10 TCID 50/ml poliovirus type log10 TCID 50/ml poliovirus type log10 TCID 50/ml total poliovirus content Standard for potency testing, 2004 In press Antigen NIBSC 02/ Rabies vaccine. Lyophilized. 16 IU / ampoule (PM-glycoprotein: 10 IU / ampoule. PM-ribonucleoprotein 135 IU / ampoule in addition to the 16 IU of rabies vaccine). 5th-International Standard, 1991 No. 822, 42nd Report Rabies inactivated virus NIBSC RAV Page 4 of 6
5 WHO International Biological Preparations Rubella vaccine (live). Lyophilized. 3.9 log10 (8 000) infectious units / vial. rubella virus NIBSC 91/ Smallpox vaccine. Lyophilized. 14 mg / ampoule. No unitage assigned. Tetanus toxoid (adsorbed). Lyophilized. 469 IU / ampoule. Tetanus toxoid, for flocculation tests. Lyophilized. 1,000 Lf / ampoule. Preparation, 1962 Standard, 2000 Reagent, 1988 No. 259, 15th Report Antigen NIBSC SMV No. 910, 51st Report Toxoid NIBSC 98/ No. 786, 39th Report Toxoid NIBSC TEFT Tuberculin, old. Liquid. 90,000 IU / ml. Standard, 1965 No. 329, 18th Report tuberculosis culture derived NIBSC TU Tuberculin, purified protein derivative (PPD), avian. Lyophilized. 500,000 IU / ampoule. Standard, 1954 No. 96, 8th Report avium culture derived NIBSC PPDA Tuberculin, purified protein derivative (PPD), bovine. Lyophilized. 58,500 IU / ampoule. Standard, 1986 No. 760, 37th Report bovis culture derived NIBSC PPD BOV Tuberculin, purified protein derivative (PPD), mammalian. Lyophilized. 5,000 IU / ampoule. Standard, 1951 No. 56, 5th Report tuberculosis culture derived NIBSC PPDT Page 5 of 6
6 WHO International Biological Preparations Typhoid vaccine (acetone-inactivated). Lyophilized. No unitage assigned. Preparation, 1960 No. 222, 14th Report salmonella typhi NIBSC TYVK Typhoid vaccine (heat-phenol-inactivated). Lyophilized. No unitage assigned. Preparation, 1960 No. 222, 14th Report salmonella typhi NIBSC TYVL Yellow fever vaccine. Lyophilized. 4.5 log 10 IU / ampoule. Standard, 2003 In press yellow fever virus NIBSC 99/ Rev.1 Page 6 of 6
PREPARATION STANDARD MATERIAL HELD AT CODE WHO/BS DOCUMENT. 1st Reference Reagent, 2009
WHO International Biological Reference Preparations Held and Distributed by the WHO International Laboratories for Biological Standards Acellular pertussis vaccine for potency assay by modified mouse challenge
WHO International Biological Reference Preparations Held and distributed by the WHO International Laboratories for Biological Standards
WHO International Biological Preparations PREPARATION STANDARD WHO TRS Activin A, human, recombinant. Lyophilized. 5 units / ampoule. 1st- Reagent, 1998 Alphafoetoprotein, human. Lyophilized. 100,000 IU
WHO International Biological Reference Preparations Held and Distributed by the WHO International Laboratories for Biological Standards
WHO International Biological Reference Preparations Held and Distributed by the WHO International Laboratories for Biological Standards PREPARATION Activin A, human, recombinant, Lyophilized., 5 units
Vaccines and other immunological antimicrobial therapy 1
Vaccines and other immunological antimicrobial therapy 1 Vaccines Vaccine: a biological preparation that provides active acquired immunity to a particular disease. Vaccine typically contains an agent that
Vaccination-Strategies
Vaccination-Strategies Active immunity produced by vaccine Immunity and immunologic memory similar to natural infection but without risk of disease. General Rule: The more similar a vaccine is to the disease-causing
Annex 1. WHO Recommendations, Guidelines and other documents related to the manufacture and quality control of biological substances used in medicine
WHO related to the manufacture and quality control of biological substances used in medicine WHO are intended to provide guidance to those responsible for the production of biological substances as well
VACCINATION. DR.FATIMA ALKHALEDY M.B.Ch.B;F.I.C.M.S/C.M.
VACCINATION DR.FATIMA ALKHALEDY M.B.Ch.B;F.I.C.M.S/C.M. IMMUNIZATION Immunization is defined as the procedure by which the body is prepared to fight against a specific disease. It is used to induce the
Armed Services Blood Program Immunization List
Immunization List NOTICE: The Department of Defense (DoD) assumes no risk for the use of this information by non-dod personnel, blood programs, or individual medical institutions. The use of this information
M I C R O B I O L O G Y
ninth edition TORTORA FUNKE CASE M I C R O B I O L O G Y a n i n t r o d u c t i o n 18 Practical Applications of Immunology PowerPoint Lecture Slide Presentation prepared by Christine L. Case Vaccine
Sanofi Pasteur: A partner in eradicating vaccine preventable diseases and improving access to vaccines
Sanofi Pasteur: A partner in eradicating vaccine preventable diseases and improving access to vaccines 1 Vaccines: the single most effective medical intervention 2 Vaccines save lives Millions of cases
Gene Vaccine Dr. Sina Soleimani
Gene Vaccine Dr. Sina Soleimani Human Viral Vaccines Quality Control Laboratory (HVVQC) Titles 1. A short Introduction of Vaccine History 2. First Lineage of Vaccines 3. Second Lineage of Vaccines 3. New
Please read Chapters 5, 6 and 7 of your vaccine text for next Wednesday s lecture. Chapters 9, 17 and 8 for next Friday s lectures
Valerie Daggett Please read Chapters 5, 6 and 7 of your vaccine text for next Wednesday s lecture Chapters 9, 17 and 8 for next Friday s lectures ppt files for first 2 lectures Past exams Principles of
9/10/2018. Principles of Vaccination. Immunity. Antigen. September 2018
Centers for Disease Control and Prevention National Center for Immunization and Respiratory Diseases Principles of Vaccination September 2018 Chapter 1 September 2018 Photographs and images included in
Temperature Intelligence Solutions. Thermostability of Vaccines
Thermostability of Vaccines Why are all vaccines sensitive to heat and some to freezing? Why is thermostability of vaccine important? What can be done to improve the thermostability of vaccines? Goals
Copyright regulations Warning
COMMONWEALTH OF AUSTRALIA Copyright regulations 1969 Warning This material has been reproduced and communicated to you by or on behalf of the University of Melbourne pursuant to part VB of the Copyright
Practical Applications of Immunology. Chapter 18
Practical Applications of Immunology Chapter 18 I. Vaccines A. Definition A suspension of organisms or fractions of organisms that is used to induce immunity (immunologic memory). The mechanism of memory
By:Reham Alahmadi NOV The production of antibodies and vaccination technology
By:Reham Alahmadi NOV 2018 The production of antibodies and vaccination technology Antibody Production The blood contains two types of white blood cell or leukocyte Phagocytes ingest bacteria by endocytosis
Principles of Vaccination
Immunology and Vaccine-Preventable Diseases Immunology is a complicated subject, and a detailed discussion of it is beyond the scope of this text. However, an understanding of the basic function of the
Bharat Biotech. Hyderabad. Type of PAC (Supplement and Notifiable / Permission Granted by CDSCO) S. No Product
Bharat Biotech Hyderabad S. No Product Type of PAC (Supplement and / Permission Granted by CDSCO) PAC Details Date of NOC in manufacturing process of Oral Polio F.No. 12-63/BHARAT/(PACOPV)/13-BD 30.08.2013
DISEASE PREVENTION & ANTIMICROBIAL USE REDUCTION: IMPACT OF VACCINATION
DISEASE PREVENTION & ANTIMICROBIAL USE REDUCTION: IMPACT OF VACCINATION Anwar Hoosen Department of Medical microbiology University of Pretoria & Tswane Academic Division, NHLS 1 VACCINE ACHIEVEMENTS At
CHAPTER ONE: EXECUTIVE SUMMARY. The Global Vaccine Industry CHAPTER TWO: INTRODUCTION TO VACCINES
CHAPTER ONE: EXECUTIVE SUMMARY The Global Vaccine Industry o Scope and Methodology o Overview o Pediatric Preventative Vaccines o The Market o Adult Preventative Vaccines o The Market o Total Market o
Recommendations to assure the quality, safety and efficacy of acellular pertussis vaccines
Annex 4 Recommendations to assure the quality, safety and efficacy of acellular pertussis vaccines Replacement of Annex 2 of WHO Technical Report Series, No. 878 Introduction 189 Background 189 Scope 191
DEPARTMENT OF DEFENSE AFHSB Reportable Events Monthly Report
DEPARTMENT OF DEFENSE AFHSB Reportable Events Monthly Report July 2016 Report Description Reportable Events among all beneficiaries received from the Services over the past 5 years are used to create ranges
DEPARTMENT OF DEFENSE AFHSB Reportable Events Monthly Report
DEPARTMENT OF DEFENSE AFHSB Reportable Events Monthly Report May 2016 Report Description Reportable Events among all beneficiaries received from the Services over the past 5 years are used to create ranges
Immunization:- Immunization is the process whereby a person is made immune or resistant to a specific infectious disease.
Group C Amr Abdel Raouf Definition:- Immunization:- Immunization is the process whereby a person is made immune or resistant to a specific infectious disease. Vaccine: is the administration of antigenic
Table Of Contents Executive Summary Introduction to Vaccines Pediatric Preventive Vaccines
Table Of Contents Executive Summary THE GLOBAL VACCINES INDUSTRY Scope and Methodology Overview Pediatric Preventative Vaccines THE MARKET Adult Preventative Vaccines THE MARKET TOTAL MARKET ISSUES AND
Expanded Programme on Immunization (EPI):
Expanded Programme on Immunization (EPI): Introduction Four to five million annual deaths could be prevented by 2015 through sustained and appropriate immunization efforts, backed by financial support.
Immunization (I) Dr. Aws Alshamsan Department of Pharmaceu5cs Office: AA87 Tel:
Immunization (I) Dr. Aws Alshamsan Department of Pharmaceu5cs Office: AA87 Tel: 4677363 aalshamsan@ksu.edu.sa Objectives of this lecture By the end of this lecture you will be able to: 1 Realize the significance
Immunizations for Children and Teens with Suppressed Immune Systems
Immunizations for Children and Teens with Suppressed Immune Systems Your child is starting treatment that will suppress the immune system. This will affect how your child s body responds to routine immunizations
Notifiable Infectious Diseases in Ireland 2001
Notifiable Infectious Diseases in Ireland 2001 Table 1. Annual number of infectious diseases notified in Ireland, 1982-2001 Infectious Disease 1982 1983 1984 1985 1986 1987 1988 1989 1990 1991 1992 1993
VACCINE MANAGEMENT. Recommendations for Handling and Storage of Selected Biologicals. January 2001 DEPARTMENT OF HEALTH AND HUMAN SERVICES
VACCINE MANAGEMENT Recommendations for Handling and Storage of Selected Biologicals January 2001 DEPARTMENT OF HEALTH AND HUMAN SERVICES DTaP: Diphtheria Toxoid, Tetanus Toxoid, Acellular Pertussis Vaccine
Vaccine. Specific defenses Immunity. natural. acquired. Live vaccines. Killed Inactivated vaccines. Cellular fraction vaccines
Introduction Vaccine has been a importance medical breakthrough in preventing morbidity and mortality from infectious diseases worldwide. Vaccination has managed to eradicate the deadly and mutilating
2016/17 Vaccination and Immunisation list of additional services and enhanced services
2016/17 Vaccination and Immunisation list of additional services and enhanced services 2016/17 Vaccination and Immunisation list of additional services and enhanced services Version number: 1 First published:
VACCINATION. C. Mhorag Hay
C. Mhorag Hay VACCINATION What you need to know: 1. The nature and function of passive and active immunization 2. The role of humoral and cellular immunity in vaccination 3. The types of vaccines currently
The Scientific Relevance of the ATT Today and from a historical Perspective
www.pei.de The Scientific Relevance of the ATT Today and from a historical Perspective Dr. Klaus Cussler EPAA International Workshop Towards global harmonization of 3Rs in biologicals 15-16 September 2015
History and aims of immunisation. Dr Anna Clarke Department of Public Health Dr. Steevens Hospital Dublin 8
History and aims of immunisation Dr Anna Clarke Department of Public Health Dr. Steevens Hospital Dublin 8 Objectives To examine the history of immunisation To explain the aim of immunisation To develop
Trends in vaccinology
Trends in vaccinology Mathieu Peeters, MD Joint Conference of European Human Pharmacological Societies and Joint Conference of European Human Pharmacological Societies and 20th Anniversary of AGAH March
Pentabio Vaccine (DTP-HB-Hib)
SUMMARY OF PRODUCT CHARACTERISTICS Product Name Pharmaceutical Form Strength Presentation : Pentabio : Suspension for injection : 1, 5 and 10 doses : Box of 10 vials @ 0.5 ml Box of 10 vials @ 2.5 ml Box
INFANRIX hexa. Combined Diphtheria-Tetanus-acellular Pertussis (DTPa), Hepatitis B, Poliovirus and Haemophilus influenzae type b vaccine
INFANRIX hexa Product Information 1(12) INFANRIX hexa Combined Diphtheria-Tetanus-acellular Pertussis (DTPa), Hepatitis B, Poliovirus and Haemophilus influenzae type b vaccine DESCRIPTION INFANRIX hexa
Vaccinology 101 for Fellows
Vaccinology 101 for Fellows Meg Fisher, MD Medical Director, The Children s Hospital Monmouth Medical Center An affiliate of the Saint Barnabas Health Care System Long Branch, NJ Disclosures I have no
Family and Travel Vaccinations
Family and Travel Vaccinations We offer the full range of baby, child and family vaccinations. We are able to tailor schedules to your child s needs or international schedule. We have a suggested vaccination
Immunization. Immunization procedure called vaccination and the immunizing agent called vaccine (or serum in historical references)
Vaccines BIT 120 Immunization Immunization: a procedure designed to increase concentrations of antibodies and/or effector T-cells which are reactive against infection (or cancer). Immunization procedure
CyberScan Vaccine Stress Assessment
DEMO CyberScan Vaccine Stress Assessment % imbalance is calculated from 0-100%, with 100% corresponding to increased stress. Level correlates to the aspect of the body affected. Levels 1-3 correspond to
Quality, safety and standards for poliomyelitis vaccines
Quality, safety and standards for poliomyelitis vaccines 7 th WHO/UNICEF consultation Geneva, 30 October 2008 Jackie Fournier-Caruana, WHO/QSS 1 Expert Committee on Biological Standardization The ECBS
CHILDHOOD VACCINATION
EPI (3) Age of Child How and Where is it given? CHILDHOOD VACCINATION Nicolette du Plessis Block 10 28/02/2012 10 weeks DTaP-IPV/Hib (2) Diphtheria, Tetanus, Acellular pertussis, Inactivated polio vaccine,
BabyJabs Vaccines. All vaccines are mercury-free We use aluminium-free vaccines wherever possible
BabyJabs Vaccines All vaccines are mercury-free We use aluminium-free vaccines wherever possible BabyJabs is a dedicated children s immunisation service, offering a choice of single and small combination
BabyJabs Vaccines. All vaccines are mercury-free We use aluminium-free vaccines wherever possible
BabyJabs Vaccines All vaccines are mercury-free We use aluminium-free vaccines wherever possible BabyJabs is a dedicated children s immunisation service, offering a choice of single and small combination
CPT 2016 Code Changes
CPT 2016 Code Changes Code Changes - Medicine New CPT 2016 New Codes Code Description 69209 Removal impacted cerumen using irrigation/lavage, unilateral 90620 Meningococcal recombinant protein and outer
Lichenase: a versatile, stable carrier molecule for vaccine and reagent development
Lichenase: a versatile, stable carrier molecule for vaccine and reagent development R. Mark Jones Center for Molecular Biotechnology, Fraunhofer USA New Cells, New Vaccines VII, From Protein to Product
2017/18 Immunisation programmes list of additional and enhanced services
2017/18 Immunisation programmes list of additional and enhanced services 2017/18 Vaccination and Immunisation list of additional and enhanced services Version number: 1 First published: April 2017 Prepared
Vaccinations for Adults
Case: Vaccinations for Adults Lisa Winston, MD University of California, San Francisco San Francisco General Hospital A 30-year old healthy woman comes for a routine visit. She is recently married and
Immunization. Historical point
Immunization Historical point In 1796 Edward Jenner s use of material from cowpox pustules to provide protection against smallpox. Louis Pasteur s 1885 rabies was the next to make an impact on human disease
History of Vaccines. Stanley A. Plotkin ADVAC HISTORY /21/ :21 AM
History of Vaccines Stanley A. Plotkin ADVAC HISTORY 2014 5/21/2014 11:21 AM 1 Sources of Information on The History of Vaccines: Short: Medium: Long: Chapter 1 of the book Vaccines, By Plotkin and Plotkin
Use of Infanrix -IPV+Hib in the infant primary immunisation schedule
Use of Infanrix -IPV+Hib in the infant primary immunisation schedule An update for registered healthcare practitioners July 2014 Quality Education for a Healthier Scotland 1 Acknowledgments Many thanks
Immunizations are among the most cost effective and widely used public health interventions.
Focused Issue of This Month Recommended by the Korean Pediatric Society, 2008 Hoan Jong Lee, MD Department of Pediatrics, Seoul National University College of Medicine E mail : hoanlee@snu.ac.kr J Korean
2018/19 Immunisation programmes list of additional and enhanced services
2018/19 Immunisation programmes list of additional and enhanced services 2018/19 Vaccination and Immunisation list of additional and enhanced services Version number: 1 First published: April 2018 Prepared
Report on the Deliberation Results
Report on the Deliberation Results July 23, 2012 Evaluation and Licensing Division, Pharmaceutical and Food Safety Bureau Ministry of Health, Labour and Welfare [Brand name] Tetrabik Subcutaneous Injection
CLINICAL MICROBIOLOGY AND IMMUNOLOGY. Microbial Mechanisms of Pathogenicity
CLINICAL MICROBIOLOGY AND IMMUNOLOGY Microbial Mechanisms of Pathogenicity -Pathogenicity - ability of pathogen to cause disease by overcoming the defenses of the host -Virulence - degree of pathogenicity
HPSC - Weekly Infectious Disease Report
HPSC - Weekly Infectious Disease Report Statutory Notifications of Infectious Diseases reported in Ireland via the Computerised Infectious Disease Reporting (CIDR) system for: Week 22, 2018 (Notification
EUROPEAN MEDICINES AGENCY DECISION. of 31 March 2009
European Medicines Agency Doc. Ref. EMEA/160106/2009 P/64/2009 EUROPEAN MEDICINES AGENCY DECISION of 31 March 2009 on the acceptance of a modification of an agreed Paediatric Investigation Plan for Purified
HPSC - Weekly Infectious Disease Report
HPSC - Weekly Infectious Disease Report Statutory Notifications of Infectious Diseases reported in Ireland via the Computerised Infectious Disease Reporting (CIDR) system for: Week 49, 2018 (Notification
HPSC - Weekly Infectious Disease Report
HPSC - Weekly Infectious Disease Report Statutory Notifications of Infectious Diseases reported in Ireland via the Computerised Infectious Disease Reporting (CIDR) system for: Week 33, 2018 (Notification
HPSC - Weekly Infectious Disease Report
HPSC - Weekly Infectious Disease Report Statutory Notifications of Infectious Diseases reported in Ireland via the Computerised Infectious Disease Reporting (CIDR) system for: Week 39, 2018 (Notification
HPSC - Weekly Infectious Disease Report
HPSC - Weekly Infectious Disease Report Statutory Notifications of Infectious Diseases reported in Ireland via the Computerised Infectious Disease Reporting (CIDR) system for: Week 50, 2018 (Notification
INFANRIX-IPV Product Information 1(13) INFANRIX IPV
INFANRIX-IPV Product Information 1(13) INFANRIX IPV NAME OF THE DRUG INFANRIX IPV vaccine is a combined diphtheria, tetanus, acellular pertussis (DTPa) and inactivated poliovirus vaccine. DESCRIPTION INFANRIX
HPSC - Weekly Infectious Disease Report
HPSC - Weekly Infectious Disease Report Statutory Notifications of Infectious Diseases reported in Ireland via the Computerised Infectious Disease Reporting (CIDR) system for: Week 38, 2018 (Notification
Immunizations June 5, Brenda Ormesher, MD Infectious Disease Peacehealth Medical Group Springfield, OR
Immunizations June 5, 2015 Brenda Ormesher, MD Infectious Disease Peacehealth Medical Group Springfield, OR Disclosures None Goals Understand basic public health impact of immunization Recognize types
HPSC - Weekly Infectious Disease Report
HPSC - Weekly Infectious Disease Report Statutory Notifications of Infectious Diseases reported in Ireland via the Computerised Infectious Disease Reporting (CIDR) system for: Week 3, 2019 (Notification
Diphtheria-Tetanus-Acellular Pertussis-Polio- Haemophilus influenzae type b Conjugate Combined Vaccine Biological Page (DTaP-IPV-Hib)
Diphtheria-Tetanus-Acellular Pertussis-Polio- Haemophilus influenzae type b Conjugate Combined Vaccine Biological Page (DTaP-IPV-Hib) Section 7: Biological Product Information Standard #: 07.211 Created
Fiscal Note for Permanent Rule Changes for North Carolina Division of Public Health
Fiscal Note for Permanent Rule Changes for North Carolina Division of Public Health Agency: Dept. Of Health and Human Services, Division of Public Health, Epidemiology Section, Communicable Disease Branch
Medical Coverage Guidelines are subject to change as new information becomes available.
IMMUNIZATIONS Coverage for services, procedures, medical devices and drugs are dependent upon benefit eligibility as outlined in the member's specific benefit plan. This Medical Coverage Guideline must
SUMMARY OF PRODUCT CHARACTERISTICS
1. NAME OF THE MEDICINAL PRODUCT Diphtheria, Tetanus and Pertussis Vaccine (Adsorbed) I.P. Injectable, Suspension for injection. 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each dose of 0.5 ml contains:
Immunity and how vaccines work
Immunity and how vaccines work Dr Mary O Meara National Immunisation Office Objectives of session An understanding of the following principles Overview of immunity Different types of vaccines and vaccine
Infanrix Hexa. Copyright , MIMS Australia Page 1 of 5
Infanrix Hexa MIMS Abbreviated Prescribing Information Diphtheria toxoid; haemophilus influenzae vaccine; hepatitis B vaccine; pertussis vaccine; poliomyelitis vaccine; tetanus toxoid GlaxoSmithKline Australia
Preventative Vaccines. Vaccines for Special Populations. Vaccinations for Adults: An Update. Vaccines Generally Available in the U.S.
Vaccinations for Adults: An Update Preventative Vaccines Need to be extremely safe Even greater issue as disease prevalence wanes or uncommon diseases targeted Lisa G. Winston, MD University of California,
VACCINATION. Magdalena E. Sobieszczyk
Magdalena E. Sobieszczyk VACCINATION GOALS: 1. Understand passive and active immunization 2. Understand the role of humoral and cell-mediated immunity in vaccination 3. Review the types of vaccines currently
Alberta Notifiable Disease Incidence
Alberta Notifiable Disease Incidence A Historical Record 1919-214 Acknowledgements Prepared by Rosa Maheden Business Analyst Contributions Kimberley Simmonds Manager, Infectious Disease, EPI Theresa Lohman
Cholera. Cholera prevention and control. Mode of Transmission. Ganges River Delta. Public health significance
* This presentation is prepared by the author in one s personal capacity for the purpose of academic exchange and does not represent the views of his/her organisations on the topic discussed. Cholera prevention
Achievements in Public Health, Impact of Vaccines Universal... Children -- United States,
1 of 6 2/10/2005 7:40 PM Weekly April 02, 1999 / 48(12);243-248 Achievements in Public Health, 1900-1999 Impact of Vaccines Universally Recommended for Children -- United States, 1990-1998 At the beginning
Adolescent vaccination strategies
Adolescent vaccination strategies Gregory Hussey Vaccines for Africa Initiative Institute of Infectious Diseases & Molecular Medicine University of Cape Town www.vacfa.uct.ac.za gregory.hussey@uct.ac.za
D-LAB HEALTH SP 725. Jose Gomez-Marquez
SP 725 Jose Gomez-Marquez 1 Vaccine Preventable Diseases Causes of 2.5 million child deaths out of 10.5 million child deaths globally, 2002 Source: WHO Wkly Epidemiol Rec. (2006) 81:189-196. 2 Rationale
14: Immunological products and vaccines
File name: Immunological Products and s Formulary BNF Original Date of issue: 30/10/2005 Last Reviewed: 23/11/2012 Version:4 Page 1 of 6 14: Immunological products and vaccines 14.1 Active immunity Live
Health Questionnaire
Health Questionnaire The information collected in this document is solely for the purpose of obtaining that which is required under the Ambulance Act of Ontario and is a condition of employment for all
IMMUNIZATION IN CHILDREN WITH CANCER
SIOP PODC Supportive Care Education Presentation Date: 05 th September 2014 Recording Link at www.cure4kids.org: http://www.cure4kids.org/ums/home/conference_rooms/enter.php?room=p2xokm5imdj Email: ahmed.naqvi@sickkids.ca
Session 27: Vaccines. Patricia Fitzgerald-Bocarsly May 18, 2009
Session 27: Vaccines Patricia Fitzgerald-Bocarsly May 18, 2009 A brief history of vaccination Immunity: comes from the Latin immunis meaning exempt Concept dates to 430 B.C. when Thucydides, the historian
PREVENTION OF INFECTIOUS DISEASES
PREVENTION OF INFECTIOUS DISEASES Loughlin AM & Strathdee SA. Vaccines: past, present and future. In Infectious Disease Epidemiology, 2 nd ed, Jones & Bartlett, 2007; p 374. Loughlin AM & Strathdee SA.
1 Principles of Vaccination Immunology and Vaccine-Preventable Diseases... 1 Classification of Vaccines... 4 Selected References...
1 Principles of Vaccination Immunology and Vaccine-Preventable Diseases... 1 Classification of Vaccines... 4 Selected References... 7 2 General Recommendations on Immunization Timing and Spacing of Vaccines...
SP.718 Special Topics at Edgerton Center: D-Lab Health: Medical Technologies for the Developing World
MIT OpenCourseWare http://ocw.mit.edu SP.718 Special Topics at Edgerton Center: D-Lab Health: Medical Technologies for the Developing World Spring 2009 For information about citing these materials or our
CONVENTIONAL VACCINE DEVELOPMENT
CONVENTIONAL VACCINE DEVELOPMENT PROBLEM Lethal germ Dead mouse LIVE VACCINES Related but harmless germ gives protection against lethal pathogen. Examples are the original pox vaccine and some TB vaccines
Creating VaCCines, ProteCting Life
Creating VaCCines, ProteCting Life PreVenting Disease through VaCCination a Constant BattLe Immunization has been a great public health success story. The lives of millions of children have been saved,
Advisory Committee on Immunization Practices VACCINE ACRONYMS
Vaccine Acronyms Page 1 of 5 Advisy Committee on Immunization Practices VACCINE ACRONYMS Vaccines Included in the Immunization Schedules f Children, Adolescents, and Adults Following is a table of standardized
Vaccines. Vaccines ( continued 1) February 21, 2017 Department of Public Health Sciences
Infectious Disease Epidemiology BMTRY 713 (A. Selassie, DrPH) Lecture 11 Vaccines Past, Present, Future Learning Objectives 1. Identify the various types of vaccines 2. Describe the role of vaccine in
EXPANDED PROGRAM OF IMMUNIZATION (EPI) Definition Program adopted by WHO since l974, it includes child immunization & vaccination of pregnant women.
EXPANDED PROGRAM OF IMMUNIZATION (EPI) Definition Program adopted by WHO since l974, it includes child immunization & vaccination of pregnant women. Strategy A. Child immunization Egyptian immunization
See 17 for PATIENT COUNSELING INFORMATION. Revised: xx/2012
HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use MENHIBRIX safely and effectively. See full prescribing information for MENHIBRIX. MENHIBRIX (Meningococcal
Guidelines for Vaccinating Pregnant Women
Guidelines for Vaccinating Pregnant Women March 2012 Guidelines for Vaccinating Pregnant Women Abstracted from recommendations of the Advisory Committee on Immunization Practices (ACIP) MARCH 2012 Risk
Coverage of Vaccines Medicaid and Child Health Plus Members
Coverage of Vaccines Medicaid and Child Health Plus Members For children between the ages 0-18, routine recommended vaccinations are covered through Vaccines for Children program [VFC]. Fidelis Care will
Infanrix IPV. Copyright , MIMS Australia Page 1 of 6
Infanrix IPV MIMS Abbreviated Prescribing Information Diphtheria toxoid; pertussis vaccine; poliomyelitis vaccine; tetanus toxoid GlaxoSmithKline Australia Section: 10(a) Vaccines - Immunology Use in pregnancy:
HEALTH REQUIREMENTS AND SERVICES: FFAD COMMUNICABLE DISEASES (EXHIBIT) REQUIREMENTS FOR EXCLUDING STUDENTS AND REPORTING CONDITIONS
REQUIREMENTS FOR EXCLUDING STUDENTS AND REPORTING CONDITIONS The information on the chart below has been collected from Department of Health rules at 25 TAC 97.3, 97.6, 97.7, and 97.132 The major criterion
Public Statement: Medical Policy. Effective Date: 01/01/2012 Revision Date: 03/24/2014 Code(s): Many. Document: ARB0454:04.
ARBenefits Approval: 01/01/2012 Effective Date: 01/01/2012 Revision Date: 03/24/2014 Code(s): Many Medical Policy Title: Immunization Coverage Document: ARB0454:04 Administered by: Public Statement: 1.
The administration of covered immunizations and vaccines also is covered.
Covered Benefit: Vaccines & Immunization Definitions: CMP Published: Yes No CMP Link: CPG Link: Pediatric, Adolescent and Adult Routine Preventative Services Immunizations and vaccinations for treatment